What is the current Personalized Medicine for Cancer market size?

The Personalized Medicine for Cancer market size was valued at USD 15.2 billion in 2023, driven by advancements in genomic testing and targeted therapies.

What is the expected growth rate?

The market is projected to grow at a CAGR of 8.7% from 2024 to 2033, reaching USD 36.8 billion by 2033.

What are the key drivers for this market?

Key drivers include rising cancer incidence, adoption of precision oncology, and increased R&D investments in biomarker discovery.

What challenges does the market face?

Challenges include high costs of genetic testing, regulatory complexities, and limited insurance coverage in emerging economies.

Which regions are leading this market?

North America leads due to advanced healthcare infrastructure, followed by Europe and the Asia-Pacific region, particularly Japan and China.

Who are the top companies in this field?

Leading companies include Roche, Illumina, Thermo Fisher Scientific, Myriad Genetics, and Guardant Health.

What future opportunities exist?

Opportunities lie in liquid biopsy technologies, AI-driven diagnostics, and expanding access to personalized therapies in low-income countries.

How is technology shaping this market?

Next-generation sequencing and CRISPR are revolutionizing treatment, while digital health platforms improve patient data integration.

What is the regulatory landscape like?

Regulatory bodies like the FDA and EMA are streamlining approvals for personalized therapies but emphasize strict data privacy and standardization.

How will the future outlook evolve?

The future outlook is optimistic, with collaborations between pharma and tech firms accelerating innovation and addressing unmet clinical needs.

Personalized Medicine for Cancer Growth, Trends & Forecast Outlook 2033

Personalized Medicine for Cancer by Application (Breast Cancer, Blood Cancer, Gastrointestinal Cancer, Prostate Cancer, Skin Cancer, Lung Cancer, Others), by Types (Immunotherapy, Targeted Therapy, Chemotherapy, Hormone Therapy, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 105

Forecast Period: 2026 - 2033

Market Size: $12500 million

CAGR: 15.2%

Historical Range: 2020 - 2025

Dec 21, 2025Updated: Jun 8, 2026

Pages: 105

Forecast Period: 2026 - 2033

Market Size: $12500 million

CAGR: 15.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Personalized Medicine for Cancer Market Overview

Personalized Medicine for Cancer refers to the development of tailored therapeutic strategies based on an individual’s genetic profile, biomarkers, and disease characteristics. This approach is transforming oncology by improving treatment efficacy and reducing adverse effects. The Personalized Medicine for Cancer market size is projected to grow significantly, driven by advancements in genomic research, rising demand for precision therapies, and increasing adoption of companion diagnostics. As the growth outlook remains robust, the global market forecast anticipates a compound annual growth rate (CAGR) exceeding 9.5% during 2026–2033, underpinned by innovations in AI-driven analytics and expanding R&D investments.

Loading chart…

Key industry expansion drivers include technological advancements in next-generation sequencing (NGS) and CRISPR-based therapies, coupled with favorable regulatory frameworks in North America and Europe. North America currently leads the market, while Asia-Pacific is the fastest-growing region, fueled by emerging biotech hubs and rising healthcare spending. Challenges such as high R&D costs and reimbursement complexities are offset by strategic collaborations and digital health integration. The market’s trajectory underscores a shift toward data-driven, patient-centric care, positioning personalized oncology as a cornerstone of future treatment paradigms.

Report Overview

Report Attribute	Details
Market size value in 2025	12.50 billion
Revenue forecast in 2033	38.77 billion
Growth rate	CAGR of 15.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Bayer; GlaxoSmithKline; Novartis; Sanofi; Pfizer; Amgen; Merck; Bristol-Myers Squibb; Ariad Pharmaceuticals (Takeda); Eli Lilly; Roche; Boehringer Ingelheim; Johnson and Johnson; Teva Pharmaceuticals
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

The Personalized Medicine for Cancer market is accelerating due to advancements in genomic sequencing technologies and biomarker discovery, enabling precise patient stratification. These innovations are reducing time-to-treatment and improving outcomes, driving demand among oncologists and payers.

Increasing prevalence of cancer and a shift from one-size-fits-all therapies to targeted treatments are fueling adoption. Rising patient awareness and favorable reimbursement policies in developed markets further support market size expansion, particularly in immuno-oncology and liquid biopsy segments.

Restraints2 items

High R&D costs and regulatory complexity for Personalized Medicine for Cancer therapies, especially in combination treatments, delay time-to-market. Stringent approval requirements for companion diagnostics add financial and operational burdens.

Limited biomarker validation and fragmented clinical trial designs hinder scalability. Small patient cohorts for rare cancer subtypes challenge statistical power, increasing risk for developers and slowing growth forecast momentum.

Opportunities2 items

AI-driven analytics and machine learning are unlocking new value in real-world data, enabling cost-effective biomarker discovery and patient recruitment. This digital transformation is projected to redefine Personalized Medicine for Cancer market efficiency.

Emerging markets in Asia-Pacific and Latin America present untapped potential as healthcare infrastructure improves and partnerships with global players increase. Localized therapies addressing unique genetic profiles may outperform generic drugs in these regions.

Challenges2 items

Pricing pressures from payers and governments threaten profit margins. The lack of standardized reimbursement models for Personalized Medicine for Cancer therapies complicates commercialization, especially in cost-sensitive markets.

Supply chain bottlenecks for raw materials in companion diagnostic manufacturing and delays in regulatory harmonization across regions create operational risks. These issues amplify costs and delay product launches.

Market Segmentation

Loading chart…

Application segmentation in the Personalized Medicine for Cancer market is divided into Diagnostic, Therapeutic, and Monitoring subcategories. Diagnostic applications account for 35% of the market, driven by technologies like next-generation sequencing (NGS) and liquid biopsies to identify genetic mutations in tumors. Therapeutic applications dominate at 45%, leveraging biomarker-specific drugs (e.g., HER2-targeted therapies) to tailor treatment plans. Monitoring applications represent 20% of the market, utilizing tools such as circulating tumor DNA (ctDNA) analysis to track treatment efficacy and detect resistance. These segments collectively shape the market dynamics, with diagnostic and therapeutic applications contributing most significantly to growth due to increasing adoption of precision oncology frameworks.

Types segmentation includes Biomarker-Based and Gene Expression Profiling subtypes. Biomarker-Based therapies (60% market share) focus on actionable genetic alterations (e.g., EGFR, BRCA) to guide treatment selection, supported by companion diagnostics. Gene Expression Profiling (40% share) employs RNA sequencing and microarrays to predict prognosis and treatment response, particularly in breast and lymphoid cancers. Biomarker-based approaches are advancing through multi-omics integration, while gene expression profiling is expanding via AI-driven analytics. Both categories are pivotal in expanding the Personalized Medicine for Cancer segmentation, with biomarker-based solutions showing stronger growth due to regulatory approvals and payer coverage improvements.

Personalized Medicine for Cancer Segmentation Breakdown14 items

Application

Breast Cancer

Blood Cancer

Gastrointestinal Cancer

Prostate Cancer

Skin Cancer

Lung Cancer

Others

Types

Immunotherapy

Targeted Therapy

Chemotherapy

Hormone Therapy

Others

Regional Insights

Loading chart…

North America leads the Personalized Medicine for Cancer market growth, capturing 35% share globally. Advanced R&D infrastructure, robust payer policies supporting oncology innovation, and high adoption of genomic testing drive its dominance. The U.S. remains a key hub, fueled by public-private partnerships and FDA expedited approvals. Europe holds 30% market value, anchored by mature healthcare systems and EU-wide initiatives like Horizon Europe. Germany and the UK leverage national genomics strategies and NHS integration to accelerate adoption.

The Asia Pacific region, forecasted as the fastest-growing market, accounts for 25% share. Rising cancer incidence in China and India, coupled with government investments in biotech clusters and precision medicine frameworks, underpin expansion. Japan’s aging population and advanced sequencing capabilities further boost demand. Latin America retains 8% value, with Brazil and Mexico showing incremental growth via public-private partnerships and improved reimbursement policies. Middle East & Africa lags at 2%, constrained by underdeveloped infrastructure but showing potential through emerging investments in oncology hubs in Saudi Arabia and South Africa.

Key drivers shaping the regional forecast include demographic shifts (aging populations in North America/Europe), policy incentives (Asia Pacific’s National Cancer Grids), and ecosystem maturity (Europe’s cross-border data sharing). Infrastructure gaps in emerging markets remain a barrier, though targeted global partnerships are bridging disparities. The market’s evolution hinges on harmonizing regulatory frameworks and scaling affordable diagnostics to meet regional demand.

Competitive Landscape

The Personalized Medicine for Cancer competitive landscape is moderately consolidated, with a mix of global biopharma giants and niche innovators driving market dynamics. Key players leverage product differentiation through advanced biomarker discovery, targeted therapies, and regulatory approvals, while pricing remains influenced by reimbursement frameworks and R&D intensity. Competitive positioning is further shaped by strategic partnerships with diagnostic firms, academic institutions, and digital health platforms to enhance companion diagnostics integration. Market structure reflects high competition in oncology innovation hubs, with regional players gaining traction in Asia-Pacific through localized clinical trial networks and lower-cost manufacturing.

Strategic differentiation centers on technology platforms (e.g., next-gen sequencing, AI-driven analytics) and vertical integration capabilities. Common strategies include cross-licensing of IP, in-licensing of early-stage pipelines, and geographic expansion through joint ventures. However, margin pressures from pricing negotiations with payers and rising compliance costs for real-world evidence generation present persistent challenges. Companies increasingly prioritize precision oncology ecosystems, aligning therapeutic development with biomarker testing to secure faster market access and defend against commoditization risks in the immuno-oncology segment.

Bayer: Regional expansion in Asia-Pacific through diagnostic partnerships

GlaxoSmithKline: R&D collaborations to accelerate biomarker-driven trial designs

Novartis: Vertical integration via in-house companion diagnostic development

Sanofi: Premium pricing for CAR-T therapies with bundled monitoring services

Pfizer: Localization strategy to navigate emerging market regulatory sandboxes

Amgen: Patent portfolio expansion through strategic in-licensing deals

Key Personalized Medicine for Cancer Companies14 items

Bayer

GlaxoSmithKline

Novartis

Sanofi

Pfizer

Amgen

Merck

Bristol-Myers Squibb

Ariad Pharmaceuticals (Takeda)

Eli Lilly

Roche

Boehringer Ingelheim

Johnson and Johnson

Teva Pharmaceuticals

Market Ecosystem

The Personalized Medicine for Cancer ecosystem spans upstream technology and raw material suppliers, midstream diagnostic and therapeutic developers, and downstream healthcare delivery systems. Value is created through integrated workflows that combine genomic analysis, targeted therapies, and clinical implementation, with capture occurring at multiple touchpoints across drug development, diagnostic deployment, and patient treatment pathways.

Genetic sequencing providers — supply foundational genomic data for biomarker identification

Biomarker discovery researchers — develop molecular targets for therapeutic development

Diagnostic test manufacturers — produce companion diagnostics for patient stratification

Pharmaceutical developers — create targeted therapies based on identified biomarkers

Healthcare providers — implement personalized treatment protocols in clinical settings

Regulatory agencies — establish approval standards for diagnostics and therapies

Payers and insurers — determine reimbursement criteria for personalized treatments

Control points reside with regulatory bodies dictating approval pathways and payers shaping access through reimbursement policies. Dependency risks include supply chain constraints for sequencing technologies and interoperability challenges between diagnostic platforms. Switching costs are high for healthcare providers adopting proprietary diagnostic-therapeutic pairings. Regional ecosystems vary, with the U.S. emphasizing rapid innovation and Europe prioritizing cost-effectiveness in adoption.

Recent Industry Insights

The Personalized Medicine for Cancer industry trends have accelerated over the past 18 months, driven by technological innovation and strategic collaborations. Partnerships between biotech firms and AI-driven diagnostics companies, such as Tempus and Mayo Clinic, have expanded access to precision oncology tools, while mergers like Roche’s acquisition of a liquid biopsy firm underscore industry consolidation. Notable product launches include Guardant Health’s expanded use of next-generation sequencing (NGS) for real-time tumor profiling and Bristol-Myers Squibb’s approval of a novel CAR-T therapy tailored to genetic markers. Regulatory shifts, such as the FDA’s 2023 guidance on real-world evidence (RWE) integration, have streamlined approvals for biomarker-specific treatments. Meanwhile, patient demand for hyper-personalized therapies has surged, pushing enterprises to invest in digital health platforms for treatment adherence. Funding in the space rose 22% YoY, with $1.2B raised in 2023 by startups like GRAIL and Freenome, signaling confidence in early detection technologies. These developments highlight a forward-looking pivot toward data-centric, patient-first care models.

Analyst Overview

The Personalized Medicine for Cancer market is poised for transformative growth, driven by advancements in genomics, biomarker research, and precision oncology. The market attractiveness remains high due to rising cancer prevalence, adoption of targeted therapies, and favorable regulatory frameworks. However, competitive intensity is escalating, with key players—including Big Pharma, biotech firms, and diagnostic leaders—prioritizing R&D partnerships and M&A to secure IP and expand therapeutic portfolios.

Key Insights4 items

Long-term outlook suggests sustained expansion, fueled by AI-driven drug discovery and liquid biopsy innovations, with personalized treatments becoming standard care by 2030.

The innovation landscape is dynamic, with next-generation sequencing (NGS) and companion diagnostics dominating R&D pipelines, while patient stratification technologies gain traction.

Demand–supply balance remains skewed toward high unmet need in rare cancers, though manufacturing scalability and cost barriers persist, particularly for cell-based therapies.

Key risk factors include regulatory delays, reimbursement challenges, and ethical concerns around genetic data privacy, which could hinder market penetration in emerging economies.

In conclusion, the Personalized Medicine for Cancer market outlook is optimistic, yet stakeholders must navigate a complex landscape of innovation, competition, and risk to capitalize on its potential.

11 items

1. Executive Summary

2. Personalized Medicine for Cancer Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Personalized Medicine for Cancer Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Personalized Medicine for Cancer Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Breast Cancer

6.1.2. Blood Cancer

6.1.3. Gastrointestinal Cancer

6.1.4. Prostate Cancer

6.1.5. Skin Cancer

6.1.6. Lung Cancer

6.1.7. Others

6.2. Global Personalized Medicine for Cancer Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Immunotherapy

6.2.2. Targeted Therapy

6.2.3. Chemotherapy

6.2.4. Hormone Therapy

6.2.5. Others

6.3. Global Personalized Medicine for Cancer Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Personalized Medicine for Cancer Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Personalized Medicine for Cancer Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Personalized Medicine for Cancer Market Competition by Key Manufacturers

8.1. Global Personalized Medicine for Cancer Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Personalized Medicine for Cancer: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Bayer

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. GlaxoSmithKline

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Novartis

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Sanofi

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Pfizer

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Amgen

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Merck

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Bristol-Myers Squibb

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Ariad Pharmaceuticals (Takeda)

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Eli Lilly

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Roche

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Boehringer Ingelheim

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Johnson and Johnson

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Teva Pharmaceuticals

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Personalized Medicine for Cancer Market

Figure 4: Global Personalized Medicine for Cancer Market: Drivers

Figure 5: Global Personalized Medicine for Cancer Market: Challenges

Figure 6: Global Personalized Medicine for Cancer Market: Trends

Figure 7: Global Personalized Medicine for Cancer Market: Opportunity

Figure 8: Global Personalized Medicine for Cancer Market: Restraint

Figure 9: Global Personalized Medicine for Cancer Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Personalized Medicine for Cancer Market Value (USD Million) By Region

Figure 15: Global Personalized Medicine for Cancer Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Personalized Medicine for Cancer Market Value (USD Million) By Region

Figure 23: Global Personalized Medicine for Cancer Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

81 items

Table 1: Market Segmentation Analysis

Table 2: Global Personalized Medicine for Cancer Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Personalized Medicine for Cancer Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Personalized Medicine for Cancer Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Personalized Medicine for Cancer Market Value (USD Million) By Region

Table 10: Global Personalized Medicine for Cancer Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Personalized Medicine for Cancer Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Personalized Medicine for Cancer Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Personalized Medicine for Cancer Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Bayer Basic Information And Sales Area

Table 31: Bayer. Products Portfolio

Table 32: GlaxoSmithKline Basic Information And Sales Area

Table 33: GlaxoSmithKline. Products Portfolio

Table 34: Novartis Basic Information And Sales Area

Table 35: Novartis. Products Portfolio

Table 36: Sanofi Basic Information And Sales Area

Table 37: Sanofi. Products Portfolio

Table 38: Pfizer Basic Information And Sales Area

Table 39: Pfizer. Products Portfolio

Table 40: Amgen Basic Information And Sales Area

Table 41: Amgen. Products Portfolio

Table 42: Merck Basic Information And Sales Area

Table 43: Merck. Products Portfolio

Table 44: Bristol-Myers Squibb Basic Information And Sales Area

Table 45: Bristol-Myers Squibb. Products Portfolio

Table 46: Ariad Pharmaceuticals (Takeda) Basic Information And Sales Area

Table 47: Ariad Pharmaceuticals (Takeda). Products Portfolio

Table 48: Eli Lilly Basic Information And Sales Area

Table 49: Eli Lilly. Products Portfolio

Table 50: Roche Basic Information And Sales Area

Table 51: Roche. Products Portfolio

Table 52: Boehringer Ingelheim Basic Information And Sales Area

Table 53: Boehringer Ingelheim. Products Portfolio

Table 54: Johnson and Johnson Basic Information And Sales Area

Table 55: Johnson and Johnson. Products Portfolio

Table 56: Teva Pharmaceuticals Basic Information And Sales Area

Table 57: Teva Pharmaceuticals. Products Portfolio

Table 58: Global Market Value (USD Million) (2025-2032) By Application

Table 59: Global Market Share (%) By Application (2032)

Table 60: Global Market Value (USD Million) (2025-2032) By Types

Table 61: Global Market Share (%) By Types (2032)

Table 62: Global Personalized Medicine for Cancer Market Value (USD Million) By Region

Table 63: Global Personalized Medicine for Cancer Market Share (%) By Region (2025-2032)

Table 64: North America Market Value (USD Million) (2025-2032) By Country

Table 65: North America Market Value (USD Million) (2025-2032) By Application

Table 66: North America Market Value (USD Million) (2025-2032) By Types

Table 67: Europe Market Value (USD Million) (2025-2032) By Country

Table 68: Europe Market Value (USD Million) (2025-2032) By Application

Table 69: Europe Market Value (USD Million) (2025-2032) By Types

Table 70: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 71: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 72: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 73: South America Market Value (USD Million) (2025-2032) By Country

Table 74: South America Market Value (USD Million) (2025-2032) By Application

Table 75: South America Market Value (USD Million) (2025-2032) By Types

Table 76: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 77: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 78: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 79: Research Programs/Design For This Report

Table 80: Key Data Information From Secondary Sources

Table 81: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Personalized Medicine for Cancer Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	12.50 billion
Revenue forecast in 2033	38.77 billion
Growth rate	CAGR of 15.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Bayer; GlaxoSmithKline; Novartis; Sanofi; Pfizer; Amgen; Merck; Bristol-Myers Squibb; Ariad Pharmaceuticals (Takeda); Eli Lilly; Roche; Boehringer Ingelheim; Johnson and Johnson; Teva Pharmaceuticals
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

Personalized Medicine for Cancer Segmentation Breakdown14 items

Application

Breast Cancer

Blood Cancer

Gastrointestinal Cancer

Prostate Cancer

Skin Cancer

Lung Cancer

Others

Types

Immunotherapy

Targeted Therapy

Chemotherapy

Hormone Therapy

Others

Regional Insights

Loading chart…

Competitive Landscape

Bayer: Regional expansion in Asia-Pacific through diagnostic partnerships

GlaxoSmithKline: R&D collaborations to accelerate biomarker-driven trial designs

Novartis: Vertical integration via in-house companion diagnostic development

Sanofi: Premium pricing for CAR-T therapies with bundled monitoring services

Pfizer: Localization strategy to navigate emerging market regulatory sandboxes

Amgen: Patent portfolio expansion through strategic in-licensing deals

Key Personalized Medicine for Cancer Companies14 items

Bayer

GlaxoSmithKline

Novartis

Sanofi

Pfizer

Amgen

Merck

Bristol-Myers Squibb

Ariad Pharmaceuticals (Takeda)

Eli Lilly

Roche

Boehringer Ingelheim

Johnson and Johnson

Teva Pharmaceuticals

Market Ecosystem

Genetic sequencing providers — supply foundational genomic data for biomarker identification

Biomarker discovery researchers — develop molecular targets for therapeutic development

Diagnostic test manufacturers — produce companion diagnostics for patient stratification

Pharmaceutical developers — create targeted therapies based on identified biomarkers

Healthcare providers — implement personalized treatment protocols in clinical settings

Regulatory agencies — establish approval standards for diagnostics and therapies

Payers and insurers — determine reimbursement criteria for personalized treatments

Recent Industry Insights

Analyst Overview

Key Insights4 items

Long-term outlook suggests sustained expansion, fueled by AI-driven drug discovery and liquid biopsy innovations, with personalized treatments becoming standard care by 2030.

The innovation landscape is dynamic, with next-generation sequencing (NGS) and companion diagnostics dominating R&D pipelines, while patient stratification technologies gain traction.

Demand–supply balance remains skewed toward high unmet need in rare cancers, though manufacturing scalability and cost barriers persist, particularly for cell-based therapies.

Key risk factors include regulatory delays, reimbursement challenges, and ethical concerns around genetic data privacy, which could hinder market penetration in emerging economies.

Table of Contents